Genetic signature may predict lung cancer response to immunotherapy
February 27, 2024
February 27, 2024
ITHACA, New York, Feb. 27 -- Cornell University issued the following news:
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.
The results, published Feb. 23 in Cell Medicine Reports, suggested that this "gene signature" could be used to identify a subclass of lung tumors that is more likely to b . . .
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.
The results, published Feb. 23 in Cell Medicine Reports, suggested that this "gene signature" could be used to identify a subclass of lung tumors that is more likely to b . . .